Global Liver Cirrhosis Therapeutics Market 2024-2028

The liver cirrhosis therapeutics market is forecasted to grow by USD 1.94 bn during 2023-2028, accelerating at a CAGR of 5.58% during the forecast period. The report on the liver cirrhosis therapeutics market provides a holistic analysis, market size and forecast, trends, growth drivers, and challenges, as well as vendor analysis covering around 25 vendors.

The report offers an up-to-date analysis regarding the current market scenario, the latest trends and drivers, and the overall market environment. The market is driven by increasing incidence of liver cancer, advancements in medical research, and increasing collaborations between pharmaceutical companies and healthcare providers.

Market Scope
Base Year	2023
End Year	2028
Series Year	2024-2028
Growth Momentum	Accelerate
YOY 2024	4.57%
CAGR	5.58%
Incremental Value	$1.94bn

Technavio's liver cirrhosis therapeutics market is segmented as below:

By Type

Oral
Injection

By End-user

Hospitals
Clinics
Research and academic institutes

By Geographical Landscape

North America
Europe
Asia
Rest of World (ROW)

This study identifies the trend towards personalized medicine as one of the prime reasons driving the liver cirrhosis therapeutics market growth during the next few years. Also, increasing emphasis on non-invasive treatment options and integration of digital health technologies will lead to sizable demand in the market.

The report on the liver cirrhosis therapeutics market covers the following areas:

Liver cirrhosis therapeutics market sizing
Liver cirrhosis therapeutics market forecast
Liver cirrhosis therapeutics market industry analysis

The robust vendor analysis is designed to help clients improve their market position, and in line with this, this report provides a detailed analysis of several leading liver cirrhosis therapeutics market vendors that include AbbVie Inc., Alnylam Pharmaceuticals Inc., Astellas Pharma Inc., AstraZeneca Plc, CSL Ltd., Eli Lilly and Co., F. Hoffmann La Roche Ltd., Gilead Sciences Inc., GlaxoSmithKline Plc, Gwo Xi Stem Cell Applied Technology, Johnson and Johnson, Kezar Life Sciences Inc., Merck KGaA, Novartis AG, Novo Nordisk AS, Pfizer Inc., Protagonist Therapeutics Inc., and Tessera Therapeutics. Also, the liver cirrhosis therapeutics market analysis report includes information on upcoming trends and challenges that will influence market growth. This is to help companies strategize and leverage all forthcoming growth opportunities.

The study was conducted using an objective combination of primary and secondary information including inputs from key participants in the industry. The report contains a comprehensive market and vendor landscape in addition to an analysis of the key vendors.

The publisher presents a detailed picture of the market by the way of study, synthesis, and summation of data from multiple sources by an analysis of key parameters such as profit, pricing, competition, and promotions. It presents various market facets by identifying the key industry influencers. The data presented is comprehensive, reliable, and a result of extensive research - both primary and secondary. The market research reports provide a complete competitive landscape and an in-depth vendor selection methodology and analysis using qualitative and quantitative research to forecast the accurate market growth.

Product Code: IRTNTR76818

1 Executive Summary

1.1 Market overview
Exhibit 01: Executive Summary - Chart on Market Overview
Exhibit 02: Executive Summary - Data Table on Market Overview
Exhibit 03: Executive Summary - Chart on Global Market Characteristics
Exhibit 04: Executive Summary - Chart on Market By Geographical Landscape
Exhibit 05: Executive Summary - Chart on Market Segmentation by Type
Exhibit 06: Executive Summary - Chart on Market Segmentation by End-user
Exhibit 07: Executive Summary - Chart on Incremental Growth
Exhibit 08: Executive Summary - Data Table on Incremental Growth
Exhibit 09: Executive Summary - Chart on Vendor Market Positioning

2 Market Landscape

2.1 Market ecosystem
Exhibit 10: Parent market
Exhibit 11: Market Characteristics

3 Market Sizing

3.1 Market definition
Exhibit 12: Offerings of vendors included in the market definition
3.2 Market segment analysis
Exhibit 13: Market segments
3.3 Market size 2023
3.4 Market outlook: Forecast for 2023-2028
Exhibit 14: Chart on Global - Market size and forecast 2023-2028 ($ billion)
Exhibit 15: Data Table on Global - Market size and forecast 2023-2028 ($ billion)
Exhibit 16: Chart on Global Market: Year-over-year growth 2023-2028 (%)
Exhibit 17: Data Table on Global Market: Year-over-year growth 2023-2028 (%)

4 Historic Market Size

4.1 Global liver cirrhosis therapeutics market 2018 - 2022
Exhibit 18: Historic Market Size - Data Table on global liver cirrhosis therapeutics market 2018 - 2022 ($ billion)
4.2 Type Segment Analysis 2018 - 2022
Exhibit 19: Historic Market Size - Type Segment 2018 - 2022 ($ billion)
4.3 End-user Segment Analysis 2018 - 2022
Exhibit 20: Historic Market Size - End-user Segment 2018 - 2022 ($ billion)
4.4 Geography Segment Analysis 2018 - 2022
Exhibit 21: Historic Market Size - Geography Segment 2018 - 2022 ($ billion)
4.5 Country Segment Analysis 2018 - 2022
Exhibit 22: Historic Market Size - Country Segment 2018 - 2022 ($ billion)

5 Five Forces Analysis

5.1 Five forces summary
Exhibit 23: Five forces analysis - Comparison between 2023 and 2028
5.2 Bargaining power of buyers
Exhibit 24: Chart on Bargaining power of buyers - Impact of key factors 2023 and 2028
5.3 Bargaining power of suppliers
Exhibit 25: Bargaining power of suppliers - Impact of key factors in 2023 and 2028
5.4 Threat of new entrants
Exhibit 26: Threat of new entrants - Impact of key factors in 2023 and 2028
5.5 Threat of substitutes
Exhibit 27: Threat of substitutes - Impact of key factors in 2023 and 2028
5.6 Threat of rivalry
Exhibit 28: Threat of rivalry - Impact of key factors in 2023 and 2028
5.7 Market condition
Exhibit 29: Chart on Market condition - Five forces 2023 and 2028

6 Market Segmentation by Type

6.1 Market segments
Exhibit 30: Chart on Type - Market share 2023-2028 (%)
Exhibit 31: Data Table on Type - Market share 2023-2028 (%)
6.2 Comparison by Type
Exhibit 32: Chart on Comparison by Type
Exhibit 33: Data Table on Comparison by Type
6.3 Oral - Market size and forecast 2023-2028
Exhibit 34: Chart on Oral - Market size and forecast 2023-2028 ($ billion)
Exhibit 35: Data Table on Oral - Market size and forecast 2023-2028 ($ billion)
Exhibit 36: Chart on Oral - Year-over-year growth 2023-2028 (%)
Exhibit 37: Data Table on Oral - Year-over-year growth 2023-2028 (%)
6.4 Injection - Market size and forecast 2023-2028
Exhibit 38: Chart on Injection - Market size and forecast 2023-2028 ($ billion)
Exhibit 39: Data Table on Injection - Market size and forecast 2023-2028 ($ billion)
Exhibit 40: Chart on Injection - Year-over-year growth 2023-2028 (%)
Exhibit 41: Data Table on Injection - Year-over-year growth 2023-2028 (%)
6.5 Market opportunity by Type
Exhibit 42: Market opportunity by Type ($ billion)
Exhibit 43: Data Table on Market opportunity by Type ($ billion)

7 Market Segmentation by End-user

7.1 Market segments
Exhibit 44: Chart on End-user - Market share 2023-2028 (%)
Exhibit 45: Data Table on End-user - Market share 2023-2028 (%)
7.2 Comparison by End-user
Exhibit 46: Chart on Comparison by End-user
Exhibit 47: Data Table on Comparison by End-user
7.3 Hospitals - Market size and forecast 2023-2028
Exhibit 48: Chart on Hospitals - Market size and forecast 2023-2028 ($ billion)
Exhibit 49: Data Table on Hospitals - Market size and forecast 2023-2028 ($ billion)
Exhibit 50: Chart on Hospitals - Year-over-year growth 2023-2028 (%)
Exhibit 51: Data Table on Hospitals - Year-over-year growth 2023-2028 (%)
7.4 Clinics - Market size and forecast 2023-2028
Exhibit 52: Chart on Clinics - Market size and forecast 2023-2028 ($ billion)
Exhibit 53: Data Table on Clinics - Market size and forecast 2023-2028 ($ billion)
Exhibit 54: Chart on Clinics - Year-over-year growth 2023-2028 (%)
Exhibit 55: Data Table on Clinics - Year-over-year growth 2023-2028 (%)
7.5 Research and academic institutes - Market size and forecast 2023-2028
Exhibit 56: Chart on Research and academic institutes - Market size and forecast 2023-2028 ($ billion)
Exhibit 57: Data Table on Research and academic institutes - Market size and forecast 2023-2028 ($ billion)
Exhibit 58: Chart on Research and academic institutes - Year-over-year growth 2023-2028 (%)
Exhibit 59: Data Table on Research and academic institutes - Year-over-year growth 2023-2028 (%)
7.6 Market opportunity by End-user
Exhibit 60: Market opportunity by End-user ($ billion)
Exhibit 61: Data Table on Market opportunity by End-user ($ billion)

8 Customer Landscape

8.1 Customer landscape overview
Exhibit 62: Analysis of price sensitivity, lifecycle, customer purchase basket, adoption rates, and purchase criteria

9 Geographic Landscape

9.1 Geographic segmentation
Exhibit 63: Chart on Market share By Geographical Landscape 2023-2028 (%)
Exhibit 64: Data Table on Market share By Geographical Landscape 2023-2028 (%)
9.2 Geographic comparison
Exhibit 65: Chart on Geographic comparison
Exhibit 66: Data Table on Geographic comparison
9.3 North America - Market size and forecast 2023-2028
Exhibit 67: Chart on North America - Market size and forecast 2023-2028 ($ billion)
Exhibit 68: Data Table on North America - Market size and forecast 2023-2028 ($ billion)
Exhibit 69: Chart on North America - Year-over-year growth 2023-2028 (%)
Exhibit 70: Data Table on North America - Year-over-year growth 2023-2028 (%)
9.4 Europe - Market size and forecast 2023-2028
Exhibit 71: Chart on Europe - Market size and forecast 2023-2028 ($ billion)
Exhibit 72: Data Table on Europe - Market size and forecast 2023-2028 ($ billion)
Exhibit 73: Chart on Europe - Year-over-year growth 2023-2028 (%)
Exhibit 74: Data Table on Europe - Year-over-year growth 2023-2028 (%)
9.5 Asia - Market size and forecast 2023-2028
Exhibit 75: Chart on Asia - Market size and forecast 2023-2028 ($ billion)
Exhibit 76: Data Table on Asia - Market size and forecast 2023-2028 ($ billion)
Exhibit 77: Chart on Asia - Year-over-year growth 2023-2028 (%)
Exhibit 78: Data Table on Asia - Year-over-year growth 2023-2028 (%)
9.6 Rest of World (ROW) - Market size and forecast 2023-2028
Exhibit 79: Chart on Rest of World (ROW) - Market size and forecast 2023-2028 ($ billion)
Exhibit 80: Data Table on Rest of World (ROW) - Market size and forecast 2023-2028 ($ billion)
Exhibit 81: Chart on Rest of World (ROW) - Year-over-year growth 2023-2028 (%)
Exhibit 82: Data Table on Rest of World (ROW) - Year-over-year growth 2023-2028 (%)
9.7 US - Market size and forecast 2023-2028
Exhibit 83: Chart on US - Market size and forecast 2023-2028 ($ billion)
Exhibit 84: Data Table on US - Market size and forecast 2023-2028 ($ billion)
Exhibit 85: Chart on US - Year-over-year growth 2023-2028 (%)
Exhibit 86: Data Table on US - Year-over-year growth 2023-2028 (%)
9.8 Germany - Market size and forecast 2023-2028
Exhibit 87: Chart on Germany - Market size and forecast 2023-2028 ($ billion)
Exhibit 88: Data Table on Germany - Market size and forecast 2023-2028 ($ billion)
Exhibit 89: Chart on Germany - Year-over-year growth 2023-2028 (%)
Exhibit 90: Data Table on Germany - Year-over-year growth 2023-2028 (%)
9.9 UK - Market size and forecast 2023-2028
Exhibit 91: Chart on UK - Market size and forecast 2023-2028 ($ billion)
Exhibit 92: Data Table on UK - Market size and forecast 2023-2028 ($ billion)
Exhibit 93: Chart on UK - Year-over-year growth 2023-2028 (%)
Exhibit 94: Data Table on UK - Year-over-year growth 2023-2028 (%)
9.10 Japan - Market size and forecast 2023-2028
Exhibit 95: Chart on Japan - Market size and forecast 2023-2028 ($ billion)
Exhibit 96: Data Table on Japan - Market size and forecast 2023-2028 ($ billion)
Exhibit 97: Chart on Japan - Year-over-year growth 2023-2028 (%)
Exhibit 98: Data Table on Japan - Year-over-year growth 2023-2028 (%)
9.11 China - Market size and forecast 2023-2028
Exhibit 99: Chart on China - Market size and forecast 2023-2028 ($ billion)
Exhibit 100: Data Table on China - Market size and forecast 2023-2028 ($ billion)
Exhibit 101: Chart on China - Year-over-year growth 2023-2028 (%)
Exhibit 102: Data Table on China - Year-over-year growth 2023-2028 (%)
9.12 Market opportunity By Geographical Landscape
Exhibit 103: Market opportunity By Geographical Landscape ($ billion)
Exhibit 104: Data Tables on Market opportunity By Geographical Landscape ($ billion)

10 Drivers, Challenges, and Trends

10.1 Market drivers
10.2 Market challenges
10.3 Impact of drivers and challenges
Exhibit 105: Impact of drivers and challenges in 2023 and 2028
10.4 Market trends

11 Vendor Landscape

11.1 Overview
11.2 Vendor landscape
Exhibit 106: Overview on Criticality of inputs and Factors of differentiation
11.3 Landscape disruption
Exhibit 107: Overview on factors of disruption
11.4 Industry risks
Exhibit 108: Impact of key risks on business

12 Vendor Analysis

12.1 Vendors covered
Exhibit 109: Vendors covered
12.2 Market positioning of vendors
Exhibit 110: Matrix on vendor position and classification
12.3 Alnylam Pharmaceuticals Inc.
Exhibit 111: Alnylam Pharmaceuticals Inc. - Overview
Exhibit 112: Alnylam Pharmaceuticals Inc. - Product / Service
Exhibit 113: Alnylam Pharmaceuticals Inc. - Key news
Exhibit 114: Alnylam Pharmaceuticals Inc. - Key offerings
12.4 Astellas Pharma Inc.
Exhibit 115: Astellas Pharma Inc. - Overview
Exhibit 116: Astellas Pharma Inc. - Product / Service
Exhibit 117: Astellas Pharma Inc. - Key news
Exhibit 118: Astellas Pharma Inc. - Key offerings
12.5 AstraZeneca Plc
Exhibit 119: AstraZeneca Plc - Overview
Exhibit 120: AstraZeneca Plc - Product / Service
Exhibit 121: AstraZeneca Plc - Key news
Exhibit 122: AstraZeneca Plc - Key offerings
12.6 CSL Ltd.
Exhibit 123: CSL Ltd. - Overview
Exhibit 124: CSL Ltd. - Business segments
Exhibit 125: CSL Ltd. - Key offerings
Exhibit 126: CSL Ltd. - Segment focus
12.7 F. Hoffmann La Roche Ltd.
Exhibit 127: F. Hoffmann La Roche Ltd. - Overview
Exhibit 128: F. Hoffmann La Roche Ltd. - Business segments
Exhibit 129: F. Hoffmann La Roche Ltd. - Key news
Exhibit 130: F. Hoffmann La Roche Ltd. - Key offerings
Exhibit 131: F. Hoffmann La Roche Ltd. - Segment focus
12.8 Gilead Sciences Inc.
Exhibit 132: Gilead Sciences Inc. - Overview
Exhibit 133: Gilead Sciences Inc. - Product / Service
Exhibit 134: Gilead Sciences Inc. - Key news
Exhibit 135: Gilead Sciences Inc. - Key offerings
12.9 GlaxoSmithKline Plc
Exhibit 136: GlaxoSmithKline Plc - Overview
Exhibit 137: GlaxoSmithKline Plc - Business segments
Exhibit 138: GlaxoSmithKline Plc - Key news
Exhibit 139: GlaxoSmithKline Plc - Key offerings
Exhibit 140: GlaxoSmithKline Plc - Segment focus
12.10 Gwo Xi Stem Cell Applied Technology
Exhibit 141: Gwo Xi Stem Cell Applied Technology - Overview
Exhibit 142: Gwo Xi Stem Cell Applied Technology - Product / Service
Exhibit 143: Gwo Xi Stem Cell Applied Technology - Key offerings
12.11 Johnson and Johnson
Exhibit 144: Johnson and Johnson - Overview
Exhibit 145: Johnson and Johnson - Business segments
Exhibit 146: Johnson and Johnson - Key news
Exhibit 147: Johnson and Johnson - Key offerings
Exhibit 148: Johnson and Johnson - Segment focus
12.12 Kezar Life Sciences Inc.
Exhibit 149: Kezar Life Sciences Inc. - Overview
Exhibit 150: Kezar Life Sciences Inc. - Product / Service
Exhibit 151: Kezar Life Sciences Inc. - Key news
Exhibit 152: Kezar Life Sciences Inc. - Key offerings
12.13 Merck KGaA
Exhibit 153: Merck KGaA - Overview
Exhibit 154: Merck KGaA - Business segments
Exhibit 155: Merck KGaA - Key news
Exhibit 156: Merck KGaA - Key offerings
Exhibit 157: Merck KGaA - Segment focus
12.14 Novartis AG
Exhibit 158: Novartis AG - Overview
Exhibit 159: Novartis AG - Business segments
Exhibit 160: Novartis AG - Key offerings
Exhibit 161: Novartis AG - Segment focus
12.15 Novo Nordisk AS
Exhibit 162: Novo Nordisk AS - Overview
Exhibit 163: Novo Nordisk AS - Business segments
Exhibit 164: Novo Nordisk AS - Key offerings
Exhibit 165: Novo Nordisk AS - Segment focus
12.16 Pfizer Inc.
Exhibit 166: Pfizer Inc. - Overview
Exhibit 167: Pfizer Inc. - Product / Service
Exhibit 168: Pfizer Inc. - Key news
Exhibit 169: Pfizer Inc. - Key offerings
12.17 Protagonist Therapeutics Inc.
Exhibit 170: Protagonist Therapeutics Inc. - Overview
Exhibit 171: Protagonist Therapeutics Inc. - Product / Service
Exhibit 172: Protagonist Therapeutics Inc. - Key offerings

13 Appendix

13.1 Scope of the report
13.2 Inclusions and exclusions checklist
Exhibit 173: Inclusions checklist
Exhibit 174: Exclusions checklist
13.3 Currency conversion rates for US$
Exhibit 175: Currency conversion rates for US$
13.4 Research methodology
Exhibit 176: Research methodology
Exhibit 177: Validation techniques employed for market sizing
Exhibit 178: Information sources
13.5 List of abbreviations
Exhibit 179: List of abbreviations